Press
Releases

March 6, 2026 Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update February 11, 2026 Jade Biosciences to Participate in Upcoming Conferences January 5, 2026 Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference December 15, 2025 Jade Biosciences Announces $45 Million Private Placement November 13, 2025 Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update November 8, 2025 Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 November 3, 2025 Jade Biosciences to Participate in Upcoming Conferences October 17, 2025 Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 October 7, 2025 Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases October 7, 2025 Jade Biosciences Announces $135 Million Private Placement